2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal Of Clinical Oncology 2020, 38: 4076-4085. PMID: 33021871, PMCID: PMC7768342, DOI: 10.1200/jco.20.01149.Peer-Reviewed Original ResearchConceptsProgression-free survivalLung cancerMutant NSCLCEGFR monoclonal antibody cetuximabSmall cell lung cancerAddition of cetuximabPrimary end pointTyrosine kinase inhibitor afatinibCell lung cancerEGFR-Mutant NonCombination of afatinibMonoclonal antibody cetuximabAdvanced diseaseAdverse eventsOverall survivalMulticenter trialLine treatmentEGFR-TKIAntibody cetuximabDose reductionInhibitor afatinibInterim analysisCetuximabInsufficient evidencePatients
2010
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Investigational New Drugs 2010, 29: 499-505. PMID: 20094773, DOI: 10.1007/s10637-009-9380-z.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerDrug-drug interactionsErlotinib groupPlacebo groupPotential drug-drug interactionsErlotinib treatment groupPlacebo-treated patientsPossible drug-drug interactionsStandard chemotherapy regimenPhase III trialsCell lung cancerAddition of erlotinibPharmacokinetics of erlotinibMetabolite OSI-420Non-compartmental modelingAUC 6Erlotinib 150Paclitaxel 200Resultant paclitaxelChemotherapy regimenIII trialsUntreated patientsConcomitant administrationMulticenter trial
2008
392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib
Soria J, Felip E, Herbst R, Hannah N, laurie S, Armand J, Shepherd F, Berman D. 392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib. European Journal Of Cancer Supplements 2008, 6: 123. DOI: 10.1016/s1359-6349(08)72326-7.Peer-Reviewed Original Research
2004
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.14_suppl.2050.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.90140.2050.Peer-Reviewed Original Research